title: Validity of the Oxford classification of IgA nephropathy in children.
abstract: BACKGROUND
  In 2009, the Oxford classification of IgA nephropathy was published. However, its validity has not been fully examined in children. This study aimed to assess this system in an independent large-scale cohort of children.
  
  
  METHODS
  We analyzed 161 consecutive children with newly diagnosed IgA nephropathy from 1977 to 1989 retrospectively. We examined the ability of each variable in the Oxford classification as a predictor of renal outcome defined as ≥ stage III chronic kidney disease (CKD) (estimated glomerular filtration rate (eGFR) <60 mL/min/1.73 m(2)) using Cox regression analysis.
  
  
  RESULTS
  The mean mesangial score, and ratios of segmental glomerulosclerosis, endocapillary hypercellularity, tubular atrophy, and crescents were 0.49, 0.8%, 13.1%, 3.3%, and 9.2% respectively. Seven cases reached ≥ stage III CKD. In univariate analyses, mesangial hypercellularity score, endocapillary hypercellularity, tubular atrophy, and crescents were significant predictors of renal outcome. In a multivariate analysis, only mesangial hypercellularity score, tubular atrophy, and crescents were significant though, depending on models. Segmental glomerulosclerosis was not a significant predictor of renal outcome. Although the significance of crescents was not addressed in the Oxford classification, crescents were important predictors of outcome.
  
  
  CONCLUSIONS
  The Oxford classification appears to be valid for predicting renal outcome in children.
authors.affiliation: Department of Pediatrics, Wakayama Medical University, 811-1, Kimiidera, Wakayama City, Wakayama 641-8509, Japan.
authors.forename: Yuko
authors.initials: Y
authors.lastname: Shima
authors.forename: Koichi
authors.initials: K
authors.lastname: Nakanishi
authors.forename: Taketsugu
authors.initials: T
authors.lastname: Hama
authors.forename: Hironobu
authors.initials: H
authors.lastname: Mukaiyama
authors.forename: Hiroko
authors.initials: H
authors.lastname: Togawa
authors.forename: Yuya
authors.initials: Y
authors.lastname: Hashimura
authors.forename: Hiroshi
authors.initials: H
authors.lastname: Kaito
authors.forename: Mayumi
authors.initials: M
authors.lastname: Sako
authors.forename: Kazumoto
authors.initials: K
authors.lastname: Iijima
authors.forename: Norishige
authors.initials: N
authors.lastname: Yoshikawa
mesh_terms: D000293:Adolescent; D017668:Age of Onset; D000893:Anti-Inflammatory Agents / Q000627:therapeutic use; D001706:Biopsy; D002648:Child; D002675:Child, Preschool; D015331:Cohort Studies; D023381:Endpoint Determination; D005260:Female; D005355:Fibrosis; D005500:Follow-Up Studies; D005920:Glomerular Mesangium / Q000473:pathology; D005922:Glomerulonephritis, IGA / Q000145:classification* / Q000473:pathology; D005923:Glomerulosclerosis, Focal Segmental / Q000473:pathology; D006801:Humans; D007166:Immunosuppressive Agents / Q000627:therapeutic use; D053208:Kaplan-Meier Estimate; D007668:Kidney / Q000473:pathology; D007678:Kidney Glomerulus / Q000473:pathology; D007684:Kidney Tubules / Q000473:pathology; D008297:Male; D011239:Prednisolone / Q000627:therapeutic use; D011507:Proteinuria / Q000209:etiology; D015203:Reproducibility of Results; D016019:Survival Analysis; D016896:Treatment Outcome; D055815:Young Adult
chemical_list: D000893:Anti-Inflammatory Agents; D007166:Immunosuppressive Agents; D011239:Prednisolone